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Abstract
Genome wide association studies (GWAS) have identified four susceptibility loci for epithelial 
ovarian cancer (EOC) with another two loci being close to genome-wide significance. We pooled 
data from a GWAS conducted in North America with another GWAS from the United Kingdom. 
We selected the top 24,551 SNPs for inclusion on the iCOGS custom genotyping array. Follow-up 
genotyping was carried out in 18,174 cases and 26,134 controls from 43 studies from the Ovarian 
Cancer Association Consortium. We validated the two loci at 3q25 and 17q21 previously near 
genome-wide significance and identified three novel loci associated with risk; two loci associated 
with all EOC subtypes, at 8q21 (rs11782652, P=5.5×10-9) and 10p12 (rs1243180; P=1.8×10-8), 
and another locus specific to the serous subtype at 17q12 (rs757210; P=8.1×10-10). An integrated 
molecular analysis of genes and regulatory regions at these loci provided evidence for functional 
mechanisms underlying susceptibility that implicates CHMP4C in the pathogenesis of ovarian 
cancer.
Evidence from twin and family studies suggests an inherited genetic component to EOC 
risk 1,2. Rare, high-penetrance allele of genes such as BRCA1 and BRCA2 account for about 
40 percent of the excess familial risk 3 and GWAS have recently identified common risk 
alleles at 9p22, 8q24, 2q31, and 19p13 4-6 with two additional loci at 3q25 and 17q21 that 
approached genome-wide significance 6. However these only explain 4 percent of the excess 
familial risk, and more loci probably exist.
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We therefore pooled the data from two GWAS to inform the selection of SNPs for a large-
scale replication. The North American study comprised four independent case-control 
studies that included 1,952 EOC cases and 2,052 controls. The second study was a two-
phase multi-center GWAS that included 1,817 EOC cases and 2,354 controls in the first 
phase and 4,162 EOC cases and 4,810 controls in the second phase. We carried out a fixed 
effects meta-analysis from the two GWAS for ~2.5 million genotyped or imputed SNPs. We 
selected 24,551 SNPs associated with the risk of either all-histology (11,647 SNPs) or 
serous ovarian cancer (12,904 SNPs) based on ranked P-values. Assays were designed for 
23,239 SNPs and included on a custom Illumina Infinium iSelect array (“iCOGS”) 
comprising 211,155 SNPs designed by the Collaborative Oncological Gene-environment 
Study (COGS) to evaluate genetic variants for association with the risk of breast, ovarian 
and prostate cancer. These SNPs were then genotyped in cases and controls from 43 
individual studies from the Ovarian Cancer Association Consortium (OCAC) that were 
grouped into 34 case-control strata (Table 1 and Supplementary tables 1 and 2). These 
included most of the samples genotyped in the initial GWAS.
Results
Association analyses
After applying quality control filters (see Online methods), we tested 22,252 SNPs for 
association with risk of all invasive EOC and for serous invasive EOC in 18,174 EOC cases 
(10,316 serous cases) and 26,134 controls. The primary analyses were based on the subjects 
of European ancestry (16,283 cases and 23,491 controls).
The associations of the four SNPs at 2q31, 8q24, 9p22 and 19p13 previously reported at 
genome-wide significance were all confirmed (Supplementary table 3). SNPs at the two 
other loci previously reported near to genome-wide significant (at 3q25 and 17q21)6 were 
also confirmed. The associated SNP at 3q25 reported by Goode and colleagues (rs2665390) 
failed design, but a correlated SNP, rs7651446 (r2=0.61) was highly significantly associated 
with invasive EOC (effect allele frequency (EAF)=0.050, per-allele OR = 1.44, 95% CI: 
1.35-1.53, P=1.5×10-28) as was rs9303542 at 17q21 (EAF=0.27, OR = 1.12, 95% CI: 
1.08-1.16, P=6.0×10-11). The Manhattan plots for all invasive EOC and serous invasive 
EOC, after excluding 176 SNPs from the six known loci, are shown in Figure 1. We 
identified three new loci at genome-wide significance (P<5×10-8), two of which were 
significant for all invasive EOC (8q21 and 10p12) and another for invasive serous EOC only 
(17q12) (Table 2). The genotype clustering for the top hits at 8q21 (rs11782652) and 17q12 
(rs757210) was good, but clustering of the top hit at 10p12 (rs7084454) was poor 
(Supplementary Fig. 1). Clustering for a second, highly correlated SNP (r2= 0.86) at this 
locus (rs1243180) was good and so the results for this SNP are presented instead.
The most significant association for all invasive EOC was rs11782652 at 8q21 (odds ratio 
(OR) = 1.19, 95% CI: 1.12-1.26, P=5.5×10-9). This SNP had been selected for replication 
because it was associated with all invasive EOC in the combined GWAS data (OR =1.20, 
95% CI: 1.07-1.36, P=0.0025). This SNP is not correlated with any other SNP in HapMap 
(Supplementary fig. 2) and was the only SNP in the selected for genotyping in COGS. 
Effects varied by histological subtype (P=0.0002), with the strongest effect in the serous 
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subtype (Table 2). There was little evidence for heterogeneity of the association by ancestry 
(P=0.55) or between the 31 European studies included (P=0.13, Supplementary fig. 3). 
Rs1243180 at 10p12 was selected for replication because it was associated with all invasive 
EOC in the combined GWAS data (OR =1.11, 95% CI: 1.04-1.19, P=0.0027) and was also 
associated with risk of all invasive EOC in the replication data (OR = 1.10, 95% CI: 
1.06-1.13, P=1.8×10-8). There is strong LD in this region and 32 other SNPs in the region 
were selected for replication (Supplementary fig. 4). T here was some heterogeneity of 
effects by tumor subtype (P=0.0007) but not by study (P=0.65, Supplementary fig. 5) or by 
population (P=0.12). At 17q12, rs757210 was selected for replication because it was 
associated with serous EOC in the combined GWAS data (OR =1.13, 95% CI: 1.04-1.23, 
P=0.0026) and was most strongly associated with the serous subtype in the replication data 
(OR = 1.12, 95% CI 1.08-1.17, P=9.6×10-10). Eight other SNPs in the region were selected 
for replication in COGS (Supplementary fig. 6). The association with all invasive EOC was 
much weaker (OR = 1.05, 95% CI 1.02-1.09, P=9×10-4); there was substantial heterogeneity 
by tumor subtype (P=<0.0001) with the risk allele for serous EOC being associated with a 
reduced risk of both clear cell and mucinous EOC (Table 2). Data from a set of fine 
mapping SNPs genotyped in this region suggest that this apparent paradox is caused by the 
presence of two independent loci for serous and clear cell cancer and that the top hit at each 
of these loci is correlated with rs757210 (CL Pearce, personal communication). There was 
also heterogeneity by ancestry for the serous subtype (P=0.034) with the risk allele 
associated with a reduced disease risk in the subjects of mixed ancestry origin, and some 
between-study heterogeneity (P=0.038, Supplementary fig. 7).
Functional and molecular analyses
The most significant risk-associated SNPs for the three novel EOC susceptibility loci are 
located in non-coding DNA sequences, but these may only be markers for the true causal 
variant(s), which could be functional coding variants, or variants in non-coding DNA 
elements or non-coding RNAs, influencing the expression of nearby target genes (cis-
regulatory effects). They may also act on genes through more distal regulation (trans-
regulatory effects) 7-11. In order to identify the most likely functional SNP and target gene 
we evaluated the putative functional role in EOC for all genes in a one-megabase region 
centred on the most significant risk-SNP at each locus. We used a combination of locus 
specific and genome-wide assays to characterize the transcribed genes (see Online methods 
and Supplementary fig. 8) and regulatory elements (Supplementary fig. 9) within 
susceptibility regions to evaluate putative functional mechanisms and identify candidate 
EOC susceptibility gene(s) at each locus.
At the 8q21 locus, the strongest associated SNP, rs11782652, is located in the first intron of 
CHMP4C. We imputed genotypes in the region to the 1000GP and tested all variants with 
MAF>0.02 for association. The log-likelihoods of the regression models were compared and 
eight SNPs with a log-likelihood within 6.91 of the most strongly associated SNP - 
equivalent to an odds of 1000:1 - were considered the most likely candidates for being the 
causal variant. Six of them lie in introns of CHMP4C but in silico analysis provided 
functional evidence for only one (rs74544416), which contains a putative SOX9 binding 
site. One is an indel (4 nucleotides) at the exon-intron border (rs137960856; alleles -/
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GTGA) but it is unlikely to have a functional impact because the next four nucleotides are 
also GTGA. Thus, even in the deleted allele the corrected exonic sequences are retained and 
it is not expected to affect splicing. The eighth SNP, rs35094336, is predicted to result in a 
coding change from Ala to Thr that may be functionally relevant (Polyphen2 score: 0.997). 
This residue is located in a C-terminal amphipatic alpha helix conserved in all CHMP4 
proteins and is important for binding to ALIX, a protein involved in the ESCRT12. Further 
studies will be necessary to determine whether this change is of functional significance and 
has an impact on ovarian cancer biology. ENCODE data from non-ovarian cancer associated 
tissues, FAIRE-seq data and mapping of enhancer elements generated in normal serous 
ovarian cancer precursor cells suggests there are two regulatory regions that may be 
influenced by risk associated SNPs; one at the CHMP4C promotor and the other in intron 
one of CHMP4C (Figure 2).
We found no evidence of a correlation between rs11782652 genotype and gene expression 
in normal ovarian/fallopian tube epithelial cells for any of the nine genes in the region 
(FABP5, PMP2, FABP4, FABP12, IMPA1, SLC10A5, ZFAND1, CHMP4C and SNX16); 
but there was a highly statistically significant association between rs11782652 and 
CHMP4C expression in primary EOCs (P=3.9×10-14) and in transformed lymphocytes 
(P=0.012). We also found evidence of association for rs11782652 with methylation status 
(mQTL) for three genes in tumour tissue; ZFAND1 (P=0.003), CHMP4C (P=0.001) and 
SNX16 (P=0.001). However, only CHMP4C methylation was negative correlated with 
expression (P=0.036).
Three genes in the region, FABP5 CHMP4C and SNX16, were significantly overexpressed 
in both EOC cell lines compared to normal tissues (P=0.002, 4.8×10-9 and 5.9×10-4 
respectively) and, where data were available, in primary EOC tissues. Finally the Catalogue 
Of Somatic Mutations In Cancer (COSMIC) database showed that four genes in the region 
IMPA1, ZFAND1, CHMP4C and SNX16 have functionally significant mutations in cancer, 
with the last three genes mutated in ovarian carcinoma (Supplementary fig. 10). These four 
genes form a highly connected co-expression network across different experimental 
conditions (Supplementary fig. 11).
Taken together these data suggest that several genes at the 8q21 locus may play a role in the 
somatic development of EOC; but the cumulative evidence indicate that CHMP4C 
(chromatin-modifying protein 4C), is the most likely candidate susceptibility gene. This is 
supported by previously published data on the function of CHMP4C. CHMP4C is involved 
in the final steps of cell division, co-ordinating midbody resolution with the abscission 
checkpoint 13 and its transcription is regulated by TP53 to enhance exosome production14. A 
more recently study has shown that CHMP4C is frequently overexpressed in ovarian tumor 
tissues, with the suggestion that it may represent a diagnostic tumor marker and therapeutic -
target for patients with the disease15.
At the 10p12 locus, six known genes (NEBL, C10Orf113, C10Orf114, C10Orf140, MLLT10 
and DNAJC1) span the one megabase region around rs1243180, which lies in an intron of 
MLLT10 (Figure 3). Based on data imputed from the 1000 Genomes Project 57 SNPs are 
candidates for being functionally significant variants. This includes variants in the 3′UTR of 
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c10orf114 and the 5′UTR of c10orf140, and a synonymous variant in MLLT10. Forty-six 
SNPs lie in introns of the MLLT10 gene, and the remaining eight are intergenic. In silico 
analyses found little or no functional evidence that any of these SNPs, including the most 
risk associated SNP rs1243180. However, after FAIREseq analysis of normal serous ovarian 
cancer precursor cells, one of these SNPs, rs10828252 (r2=0.87 with rs1243180), was found 
to coincide with a region of open chromatin, which probably corresponds to the promotor of 
MLLT10 (Figure 3). Although rs10828252 is not positioned directly at the apex of the 
signal, but rather within the upstream portion, it is well established that open chromatin at 
transcription start sites of genes result from the coordinated influence of numerous 
transcription factors (TF) binding within the vicinity, and therefore it is highly plausible that 
rs10828247 is modulating one of these TF binding sites. The resulting shape and position of 
the FAIRE-seq signal may therefore represent the resulting effects of putative TF binding at 
rs10828247 working in concert with others in close proximity.
This finding suggests a possible mechanism for susceptibility to EOC at this locus through 
subtle variations in promotor regulation of MLLT10. However, eQTL analysis found no 
significant associations between genotypes of either rs1243180 or rs10828252 and MLLT10 
expression in normal tissues. We did observe eQTL associations for two other coding genes 
in the region, NEBL and C10orf114 (P=0.04 and 0.03 respectively). C10orf114 expression 
was also associated with rs1243180 genotypes in primary EOCs (P=0.02) as was C10orf140 
(P=0.02). Methylation at both C10orf140 and MLLT10 was associated with rs1243180 
genotype in primary EOC tissues (P=0.03 and 0.05 respectively), and both genes show 
significant negative correlation between methylation and expression (P=0.0016 and 0.002 
respectively). C10orf140 also shows a significant difference in methylation in tumors 
compared to normal tissue (P=1.9×10-5).
Four genes (NEBL, C10orf114, C10orf140 and MLLT10) were significantly overexpressed 
in EOC cell lines compared to normal tissues (P≤0.01) of which two, C10orf114, and 
MLLT10, also showed elevated overexpression in primary EOCs (Figure 3). Correlations 
between gene expression and DNA copy number variation at this locus in primary EOCs 
suggest that overexpression of the C10orf114 and MLLT10 genes are driven by copy number 
variation. NEBL is the only gene with reported mutations in ovarian cancer (Supplementary 
fig. 10). Together, these data suggest that NEBL, C10orf114, C10orf140 and MLLT10 gene 
may all play a role in ovarian cancer development, and any of these four genes could be the 
target susceptibility gene at this locus. However, there is no other evidence to implicate 
C10orf114 or C10orf140 in EOC or to suggest a rationale that may underlie disease 
susceptibility. More is known about the function of NEBL and MLLT10 although neither 
gene has previously been implicated in ovarian cancer. MLLT10 (mixed-lineage leukemia 
(trithorax homolog, Drosophila) translocated to 10) encodes a transcription factor and has 
been identified as a partner gene involved in several chromosomal rearrangements resulting 
in leukaemia16. More than 60 MLL fusion partner genes have been described at the 
molecular level, including a recently reported fusion NEBL-MLL17. NEBL (Nebulette) 
encodes a nebulin like protein that is abundantly expressed in cardiac muscle, and has been 
implicated in the genetics of sudden cardiac death syndrome and cardiac remodeling18. This 
evidence does not support directly a role for these genes in ovarian cancer, but the first 
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common gene-fusion in serous ovarian cancers (ESRRA-C11orf20 ) has been reported 
recently and provides an underlying hypothesis for the involvement of genes at this locus in 
EOC development19.
At chromosome 17q12, the most significant SNP, rs757210, lies in an intron of HNF1B and 
is associated with serous subtype ovarian cancer. Based on data imputed from the 1000 
Genomes Project nine SNPs are candidates for being the causal variant. SNPs in this region 
have been associated with diabetes 20, endometrial cancer21 and prostate cancer22. There are 
thirteen genes in the 1MB region on either side of this SNP (ACACA, C17orf78, TADA2L, 
DUSP14, AP1GBP1, DOX52, HNF1B, TBC1D3F, TBC1D3 MRPL45, GRP179, SOCS7, 
and ARHGAP23). Seven of these (DUSP14, HNF1B, TBC1D3, TBC1D3F, MRPL45, 
SOCS7 and ARHGAP23) were overexpressed in EOC cell lines and primary tumors 
compared to normal tissues (Figure 4 and Supplementary fig. 8.iii) indicating they may 
play a role in EOC. HNF1B is a strong candidate gene target at this locus; it has been 
extensively studied in EOC and is used as a biomarker for subtype stratification of EOC 
tumors23, in particular to distinguish clear cell from other EOC subtypes. Consistent with 
this, overexpression of HNF1B in EOC cell lines was largely driven by higher expression in 
clear cell EOC cell lines (Figure 4)24. However, HNF1B shows lower expression in primary 
serous EOCs compared to normal tissues, which may suggest a different role for this gene in 
clear cell compared to serous tumours 25. The phenotypic consequences of HNF1B 
knockdown in clear cell EOC cell lines also suggest it may behave as an oncogene in the 
development of this subtype.26. We found no correlation between HNF1B expression and 
DNA copy number variation at this locus in primary EOCs; but a highly statistically 
significant inverse correlation between HNF1B expression and methylation (P=2.1×10-6) 
which implies the mechanism for overexpression of this gene is epigenetic.
RNAseq analysis of normal ovarian cancer precursor tissues indicates that HNF1B is 
expressed at extremely low levels (Figure 4), which restricts the extent to which the 
function of this gene in normal ovarian cancer precursor tissues can be studied. We found no 
evidence for eQTL associations between rs757210 and the expression of any gene in normal 
tissues throughout the region, but we observed a strong mQTL association between 
rs757210 and HNF1B methylation (P=0.009) (Figure 4; Supplementary table 4) in 
primary serous EOCs. The minor (risk) allele of rs757210 was associated with lower 
methylation and therefore is predicted to be associated with increased HNF1B expression. In 
the absence of additional functional data it is difficult to interpret these findings; but given 
the possible role of HNF1B as an oncogene in the development of clear cell ovarian cancer, 
it may be that increased HNF1B expression at an early stage in the development of ovarian 
cancer precursor tissues, driven by the risk variant(s) underlying susceptibility, has increased 
oncogenic activity in the proportion of serous ovarian that carry this allele.
Overall, the functional data we have generated do not point strongly to any one gene at 
17q12 as the functionally relevant gene mediating the genetic association with disease. 
However, when combined with a large body of previous work data implicating HNF1B in 
ovarian cancer development, it suggests that this is the strongest candidate, and the mQTL 
and methylation-expression associations suggest a role for genetic variants influencing 
HNF1B expression and disease susceptibility through epigenetic regulation.
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Discussion
This study has demonstrated the strength of large-scale collaboration in genetic association 
studies. We have identified three novel common alleles that confer susceptibility to EOC 
and confirmed two loci that had been previously reported at near genome-wide significance. 
Molecular analyses of genes at these loci, combining publicly available datasets and 
systematic, large-scale experiments point to a small number of candidate gene targets that 
may play a role in EOC initiation and development. However, the effects of the novel loci 
were modest, and together they explain less than 1 per cent of the excess familial risk of 
EOC, with about 4 per cent explained by all known loci with common susceptibility alleles. 
The lack of heterogeneity between studies of varying designs, carried out in different 
populations and the high levels of statistical significance indicate that these are robust 
associations. Fewer common susceptibility loci have now been found for EOC than for 
several other common cancers including breast, colorectal and prostate cancer27. It seems 
unlikely that the underlying genetic architecture for EOC susceptibility is substantially 
different from other cancers. This suggests that a key factor limiting our ability to detect 
susceptibility loci is sample size – the power of this study to detect risk alleles across a range 
of likely effect sizes is modest (Supplementary fig. 12). However, EOC is less common 
than these cancers and has a higher mortality and recruiting extremely large numbers of 
cases will be difficult. Disease heterogeneity will also reduce power if a substantial 
proportion of EOC susceptibility alleles are subtype specific. All EOC susceptibility loci so 
far identified are strongly associated with serous EOC, which is also the most common 
subtype. Both the discovery and replication phases of this study were weighted towards 
identifying serous associated risk alleles. It seems likely that additional common risk loci for 
clear cell, endometrioid and mucinous EOC subtypes also exist and await identification.
Several EOC susceptibility alleles have now been identified that increased risk of multiple 
cancers. For example, an increased risk of estrogen-receptor-negative breast cancer is 
associated with the EOC susceptibility allele at 19p135,28 and the EOC susceptibility allele 
at the 17q12 locus reported in this manuscript is also associated with risk of endometrial 
cancer21 and prostate cancer22. Several of the loci containing EOC susceptibility alleles 
have been found to harbour different susceptibility alleles for other cancers. For example, 
Michailidou and colleagues 29 have found an association between rs7072776 at 10p12 and 
breast cancer. This SNP is ~120kb centromeric to and partially correlated with rs1243180 
(r2=0.51). Michailidou and colleagues also report an association of rs11780156 at 8q24 with 
breast cancer. The new locus lies ~300kb telomeric of the known locus for ovarian cancer 
(rs10088218)6, but is uncorrelated with it (r2=0.02). Both loci lie ~400kb 3′ of MYC. 
Previous GWAS have identified multiple loci 5′ of MYC and associated with different 
cancer types, including a locus for breast cancer. These associations may reflect tissue-
specific regulation of key genes and understanding the functional mechanisms underlying 
genetic associations at the same locus for different phenotypes may provide insights into 
more general mechanisms of disease etiology and cancer development.
Assuming a log-additive model of interaction between loci, the currently know loci (Table 2 
and Supplementary Table 3) define a genetic risk profile with a combined variance for the 
log relative risk distribution of 0.057. Such a distribution has limited discriminatory ability; 
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the estimated relative risks at the 5th and 95th centiles are 0.63 and 1.48 respectively. 
However, based on what is known about the architecture of genetic susceptibility for other 
cancers it is likely that many more common susceptibility alleles exist. The discovery of 
genetic association with ovarian cancer may be enhanced by taking advantage functional 
annotation data and the analysis of gene-gene and gene-environment interactions using a 
genome-wide approach. Continued international efforts are needed to establish new case-
control studies, to expand existing case-control studies and to improve the pathological 
characterisation of the cases in these studies in order to unravel the inherited genetic basis of 
the disease. In combination with rarer risk alleles and other risk factors, genetic profiling 
may provide sufficient discrimination to justify targeted ovarian cancer prevention.
URLs
1000 Genomes Project: http://www.1000genomes.org/page.php
COSMIC: http://www.sanger.ac.uk/genetics/CGP/cosmic/
GeneMANIA: http://genemania.org/
MACH: http://www.sph.umich.edu/csg/abecasis/MACH/
NCBI Unigene: http://www.ncbi.nlm.nih.gov/unigene
The Cancer Genome Atlas Project: http://cancergenome.nih.gov/
The Cancer Genome Atlas Project data bioprtal: http://www.cbioportal.org/
The Wellcome Trust Case Control Consortium: http://www.wtccc.org.uk/
Online Methods
SNP selection
We combined the results from two ovarian cancer GWAS from North America and the UK. 
Details of these studies have been published previously 4,31 and are described in the 
Supplementary note. In order to account for different marker sets and to improve genome 
coverage, imputation to HapMap2 was performed using 60 CEU founders as reference. Data 
on 2,508,744 genotyped SNPs or SNPs imputed with r2>0.3 were available for analysis.
The North American and UK studies were analysed separately and the results combined 
using fixed effects meta-analysis. The 2.5 million SNPs were ranked according to the P-
values for each of four analyses performed: North America study only (all invasive and 
serous histology) and combined GWAS meta-analysis (all invasive and serous histology). 
The minimal ranking for each SNP was obtained across the four sets of results. SNPs with 
minor allele frequency less than 3 percent or SNPs that were already genotyped or in perfect 
LD with UK GWAS phase 2 SNPs were excluded. We acquired the design score for each 
SNP using the Illumina Assay Design Tool and removed SNPs that were redundant or 
predicted to perform poorly. In total, 24,552 SNPs were included on the iCOGS custom 
genotyping array (see Supplementary materials).
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Study populations
A total of 47,630 samples from 43 studies in OCAC were genotyped of which 44,308 passed 
QC, including 18,174 (10,315 serous) cases and 26,134 controls (Supplementary table 1). 
The HapMap samples for European (CEU, n=60), African (YRI, n=53) and Asian (JPT
+CHB, n=88) populations were also genotyped using the iCOGS array.
SNP genotyping
Genotyping was conducted using an Illumina Infinium iSelect BeadChip in six centres, of 
which two were used for OCAC - McGill University and Génome Québec Innovation 
Centre (n=19,806) and the Mayo Clinic Medical Genome Facility (n=27,824). Each 96-well 
plate contained 250 ng genomic DNA (or 500 ng whole-genome amplified DNA). Raw 
intensity data files for all consortia were sent to the COGS data co-ordination centre at the 
University of Cambridge for centralized genotype calling and QC. Genotypes were called 
using GenCall 32. Initial calling used a cluster file generated using 270 samples from 
Hapmap2. These calls were used for ongoing QC checks during the genotyping. To generate 
the final calls used for the data analysis, we first selected a subset of 3,018 individuals, 
including samples from each of the genotyping centres, each of the participating consortia, 
and each major ethnicity. Only plates with a consistently high call rate in the initial calling 
were used. The HapMap samples and ~160 samples that were known positive controls for 
rare variants on the array were used to generate a cluster file that was then applied to call the 
genotypes for the remaining samples. We also investigated two other calling algorithms: 
Illumnus 33 and GenoSNP 34, but manual inspection of a sample of SNPs with discrepant 
calls indicated that GenCall was invariably superior.
Sample QC
One thousand two hundred and seventy three OCAC samples were genotyped in duplicate. 
Genotypes were discordant for greater than 40 percent of SNPs for 22 pairs. For the 
remaining 1,251 pairs, concordance was greater than 99.6 percent. In addition we identified 
245 pairs of samples that were unexpected genotypic duplicates. Of these, 137 were 
phenotypic duplicates and judged to be from the same individual. We used identity-by-state 
to identify 618 pairs of first-degree relatives. Samples were excluded according to the 
following criteria: 1) 1,133 samples with a conversion rate of less than 95 percent; 2) 169 
samples with heterozygosity >5 standard deviations from the intercontinental ancestry 
specific mean heterozygosity; 3) 65 samples with ambiguous sex; 4) 269 samples with the 
lowest call rate from a first-degree relative pair 5) 1,686 samples that were either duplicate 
samples that were non-concordant for genotype or genotypic duplicates that were not 
concordant for phenotype. Thus, a total of 44,308 subjects including 18,174 cases and 
26,134 controls were available for analysis. Of these, 2,482 had been in the North American 
GWAS, 1,641 were in the phase 1 of the UK GWAS and 8,463 in Phase 2 of the UK 
GWAS.
SNP QC
Of 211,155 SNP assays successfully designed and included on the array, SNPs were 
excluded according to the following criteria: (1) 1,311 SNPs without a genotype call; (2) 
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2,857 monomorphic SNPS; (3) 5,201 SNPs with a call rate less than 95 percent and MAF > 
0.05 or call rate less than 99 percent with MAF < 0.05; (4) 2,194 SNPs showing evidence of 
deviation of genotype frequencies from Hardy-Weinberg equilibrium (p < 10-7); (5) 22 
SNPS with greater than 2 percent discordance in duplicate pairs. Overall, 94.5 percent 
passed QC. Genotype intensity cluster plots were visually inspected for the most strongly 
associated SNPs at each newly identified locus.
Statistical methods
We used the program LAMP35 to assign intercontinental ancestry based on the genotype 
frequencies for the European, Asian and African populations. Subjects with greater than 90 
percent European ancestry were defined as European (n=39,944) and those with greater than 
80 percent Asian or African ancestry were defined as being Asian (n=2,388) and African 
respectively (n=387). All other subjects were defined as being of mixed ancestry (n=1,770). 
We then used a set of 37,000 unlinked markers to perform principal components analysis 
within each major population subgroup 36. To enable this analysis on very large samples we 
used an in-house programme written in C++ using the Intel MKL libraries for eigenvectors 
(available at http://ccge.medschl.cam.ac.uk/software/).
Unconditional logistic regression treating the number of alternate alleles carried as an 
ordinal variable (log-additive, co-dominant model) was used to evaluate the association 
between each SNP and ovarian cancer risk. A likelihood ratio test was used to test for 
association, and per-allele log odds ratios and 95 percent confidence limits were estimated. 
The likelihood ratio test has been shown to have greater power than alternatives such as the 
Wald test and score test for rare variants37. Separate analyses were carried out for each 
ancestry group. The model for European subjects was adjusted for study and population 
substructure by including study-specific indicators and the first five eigenvalues from the 
principal components analysis in the model. For analysis of the Asian and other ancestry 
groups, the first five ancestry-specific principal components were included in the model, and 
one principal component was included in the model for analysis of subjects of African 
ancestry. The number of principal components was chosen based on the position of the 
inflexion of the principal components scree plot (Supplementary fig. 13). We tested for 
sub-type specific heterogeneity by comparing genotype frequencies in the four case subtypes 
using the Kruskal-Wallis test. We tested for heterogeneity of ORs by study and ancestry 
using the method of Breslow and Day 38.
In order to assess the magnitude of confounding due to cryptic population substructure, we 
tested the 147,722 SNPs that not been selected as candidates for ovarian cancer 
susceptibility. Inflation in the test statistics (λ) was estimated by dividing the median of the 
test statistic by 0.455 (the median for the χ2 distribution on 1df). The inflation was converted 
to an equivalent inflation for a study with 1000 cases and 1000 controls (λ1000) by adjusting 
by effective study size, namely
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where n is the number of cases and m the number of controls in each study stratum, k. In 
analyses restricted to European subjects and adjusted only for study there was a small 
inflation of the test statistics (λ = 1.13, λ1000 = 1.007). This was reduced to 1.078 (λ1000 = 
1.004) after adjusting for five principal components. Heterogeneity of odds ratios between 
studies was tested with Cochran's Q statistic.
Functional studies
We performed the following assays for each gene in the one megabase region centred on the 
most significant SNP at each locus (see Supplementary note for details): (1) Gene 
expression in EOC cell lines (n=50) and normal precursor cells and tissues for ovarian 
cancers - ovarian surface epithelial cells (OSE) and fallopian tube secretory epithelial 
(FTSE) cells (n=73); (2) CpG island methylation analysis in high grade serous EOC (n=106) 
and normal tissues (n=7).
We also evaluated these genes in silico, using bioinformatics tools to mine publicly 
available somatic genetic data generated for primary EOCs and other cancer types. These 
were The Cancer Genome Atlas (TCGA) data for ~500 high grade serous EOCs (gene 
expression, somatic mutation, DNA copy number variation, eQTL, and methylation data) 25 
and the Catalogue Of Somatic Mutations In Cancer (COSMIC) 39 analysis of mutations in 
genes curated from the published literature and data from whole genome resequencing of 
cancer samples, undertaken by the Cancer Genome Project. We generated co-expression 
networks for genes in each locus using GeneMANIA, a large dataset of gene expression 
studies (n=154) 40.
All these data enabled us to: (1) compare gene expression in tumor and normal epithelium 
(EOC cell lines/normal cell lines and TCGA tumors/normal tissue), (2) test for association 
between copy number alteration and gene expression at each locus (3) compare gene 
methylation status in tumor and normal tissue (4) carry out a gene expression quantitative 
trait locus (eQTL) analysis to evaluate associations between germline genotype and gene 
expression in lymphoblastoid cell lines, normal serous EOC precursor tissues and tumors, 
and (5) carry out a methylation quantitative trait locus (mQTL) analysis to evaluate 
associations between germline genotype and gene methylation in tumors (Supplementary 
figs. 8i-iii).
We used data from the ENCyclopedia Of DNA Elements (ENCODE)7 to evaluate the 
overlap between regulatory elements in non-coding regions and risk associated SNPs at the 
three loci. ENCODE describes regulatory DNA elements (e.g. enhancers, insulators and 
promotors) and non-coding RNAs (e.g. micro-RNAs, long non-coding and piwi-interacting 
RNAs) that may be targets for susceptibility alleles (Supplementary figs. 9i-iii). However, 
ENCODE does not include data for EOC associated tissues, and activity of such regulatory 
elements often varies in a tissue specific manner 7,41. Therefore, we profiled the spectrum of 
non-coding regulatory elements in OSE and FTSE cells using a combination of 
formaldehyde assisted isolation of regulatory elements sequencing (FAIRE-seq) and RNA 
sequencing (RNA-seq) (Supplementary figs. 9i-iii). We also analysed regulatory regions in 
early-stage transformed OSE cells. For all regulatory biofeatures spanning the one megabase 
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region at each locus, we evaluated their overlap with the most strongly associated SNP and 
all SNPs correlated with an r2≥0.8.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plot showing association between genotype of 22,076 SNPs and risk of A) all 
invasive epithelial ovarian cancer and B) serous invasive epithelial ovarian cancer
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Figure 2. Summary of the functional analyses of the 8q21 locus
(A) Genomic map of a one-megabase region at 8q21 centered on the most statistically 
significant SNP, rs11782652. The location and size of all nine known protein-coding genes 
(grey) in the region are shown relative to the location of rs11782652 (red dashed line). (B) 
Expression analysis for all genes at the 8q21 locus performed in epithelial ovarian cancer 
(EOC) cell lines (n=50) and normal ovarian surface epithelial cell (OSEC) plus fallopian 
tube secretory epithelial cell (FTSEC) lines (n=73) illustrating the relative levels expression 
for each gene in tumor (T) compared to normal (N) cell lines (*p<0.05, ***p<0.001). (C) 
The ZFAND1 result from cell line studies does not replicate in the TCGA nor the MD 
Anderson primary tumor expression dataset. However, increased expression of CHMP4C 
gene in primary, high-grade serous ovarian tumors (T) compared to normal (N) tissues was 
confirmed in expression data for primary tissues (MD Anderson data). (D) Expression 
quantitative trait locus (eQTL) analysis: Gene expression is shown relative to the germline 
genotypes for individuals carrying minor/heterozygous allele (AG/GG) and common alleles 
(AA) for rs11782652. (i) FABP5 and (ii) CHMP4C show positive eQTL associations in 
lymphoblastoid cell lines. (iii) A highly significant eQTL association with rs11782652 
genotype and CHMP4C expression is also seen in primary tumors (TCGA data). (E) 
Methylation quantitative trait locus (mQTL) analysis showing methylation status in 277 high 
grade serous ovarian cancers relative to genotypes for rs11782652. (F) Functional enhancer 
mapping: A 40kb region was tested for the presence of enhancer regions by transfection of 
2kb tiling clones into immortalized OSECs30. Activity of the luciferase reporter is shown as 
fold change in luciferase activity relative to pGL3-BP control. A novel enhancer region in 
OSECs is indicated by the red box. See Supplementary figure 8i and 9i for additional 
molecular analysis of all genes at this locus.
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Figure 3. Summary of the functional analysis of the 10p12 locus
(A) Genomic map of a one-megabase region at 10p12 centred on the most statistically 
significant SNP, rs1243180. The location and approximate size of all six known protein-
coding genes (grey) and one microRNA (blue) in the region are shown relative to the 
location of rs1243180 (red dashed line). (B) Expression analysis for all genes at this locus 
performed in EOC cell lines (T) and normal (N) OSEC and FTSEC lines illustrating the 
relative expression levels for each gene (** p<0.01, ***p<0.001). (C) eQTL analysis 
demonstrates significant associations between genotype at rs1243180 and expression of (i) 
NEBL and (ii) C10orf114 in early passage primary OSEC/FTSEC cultures. (D) (i) A 
positive eQTL association between C10orf114 genes expression and genotype at rs7098100 
(r2=0.86with rs1243180) was also observed in primary high-grade serous ovarian tumors 
(TCGA). (E) Methylation analysis of 277 high-grade serous ovarian tumors (T) compared to 
normal ovarian tissues (N) (n=7); methylation at CpG sites near to C10orf114 show 
significantly less methylation than in normal samples, which may suggest that the increased 
expression of this gene in tumors is partly due to loss of methylation. (F) Expression versus 
copy number in TCGA tumors. MLLT10 and NEBL genes show a trend for higher levels of 
gene expression found in tumors with increased DNA copy number at 10p12; 1 = 
heterozygous loss; 2 = Diploid; 3 = Copy number gain; 4 = Amplification (G) 
Formaldehyde assisted isolation of regulatory elements sequencing (FAIRE-seq) performed 
in normal OSECs and FTSECs, relative to all SNPs correlated with r2≤0.8 to rs1243180. 
The SNP rs10828247 coincides with a region of open chromatin at the 5′ end of the 
MLLT10 gene. See Supplementary figure 8ii and 9ii for additional information for all genes 
at this locus.
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Figure 4. Summary of the functional analysis of the 17q locus
(A) Genomic map of a one-megabase region at 17q12 centered on the most statistically 
significant SNP, rs757210. The location and approximate size of all thirteen known protein-
coding genes (grey) in the region are shown relative to the location of rs757210 (red dashed 
line). (B) Expression analysis for all genes at this locus performed in ovarian tumor (T) cell 
lines and normal (N) OSEC and FTSEC primary cultures illustrates the relative levels of 
expression for each gene (** p<0.01, ***p<0.001). (C) Overexpression of HNF1B detected 
in EOC cells compared to OSECs/FTSECs was largely driven by the high expression of this 
gene in clear cell EOC cell lines. HNF1B is an established clear cell EOC biomarker 23(D) 
Methylation analysis of 277 high-grade serous ovarian tumors (T) compared to normal 
ovarian tissues (N) (n=7) shows significant hypermethylation of CpG sites upstream of 
SYNRG and HNF1B in tumors (T) compared to normal (N) tissues. (E) mQTL analysis 
showing methylation status of SYNRG and HNF1B genes in primary high grade serous 
ovarian cancers relative to germline genotypes for individuals carrying minor/heterozygous 
allele (AG/GG) and common alleles (AA) for rs757210. Only methylation at the HNF1B 
gene shows a significant association with genotype at this locus. See Supplementary figure 
8iii and 9iii for additional information for all genes at this locus.
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